With the massive accumulation of wealth and talent granted to capitalist countries that occupy the top of the imperialist world order, they have highly developed, high-tech pharmaceutical and biotechnology industries. Infused with federal funding, private corporations developed novel vaccines using cutting-edge mRNA technology. These vaccines could theoretically be quickly tweaked to respond to mutant virus variants and could one day provide a universal flu vaccine, or even possibly an effective HIV vaccine. Unlike older vaccines, their production does not require handling live viruses, thus increasing safety at labs and production facilities.
The vaccine story is not just being written by Pfizer and Moderna. Cuba and China are vaccine leaders, but they are charting a much different course than capitalist countries. Their vaccine development is state-led and owned collectively by the people, not big corporations.
Cuba opened its first biotech research and production center in 1981. The industry now operates under BioCubaFarma, the Cuban organization of Biotechnology and Pharmaceutical Industries. It is a network of 34 publicly owned companies and scientific institutions working together to coordinate a planned, societywide approach to pharmaceuticals and vaccines.
The Center of Genetic Engineering and Biotechnology (CIGB) carries out research, development, and production in the areas of human and animal vaccines, therapeutic molecules, such as monoclonal antibodies, and genetically modified plants. Cuba’s Finlay Institute is the country’s premier vaccine research and development center, known for developing the world’s first meningitis B vaccine over 30 years ago. (tinyurl.com/h242znwe).
For a small country of 11 million people, under heavy sanctions from and an illegal blockade by the U.S., Cuba’s biomedical sector is unusually sophisticated compared not only to its peers in the Global South, but to many developed capitalist countries. It now has five COVID-19 vaccines in development, with two in stage III clinical trials named Soberana-02 and Abdala.
(tinyurl.com/s8urns8z) It has signed contracts to produce vaccines in Venezuela and Iran, greatly expanding the scale of the international vaccine effort. It is developing vaccines that can be stored at room temperature for weeks, making them attractive to developing tropical countries.
[premium_newsticker id="211406"]
The views expressed are solely those of the author and may or may not reflect those of The Greanville Post
YOU ARE FREE TO REPRODUCE THIS ARTICLE PROVIDED YOU GIVE PROPER CREDIT TO THE GREANVILLE POST
VIA A BACK LIVE LINK.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License